Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Research & Development (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Research & Development for 7 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 36.33% to $28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.2 million through Dec 2025, down 21.92% year-over-year, with the annual reading at $150.2 million for FY2025, 21.92% down from the prior year.
  • Research & Development hit $28.6 million in Q4 2025 for Allogene Therapeutics, down from $31.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $80.2 million in Q1 2023 to a low of $28.6 million in Q4 2025.
  • Historically, Research & Development has averaged $53.1 million across 5 years, with a median of $53.1 million in 2021.
  • Biggest five-year swings in Research & Development: soared 39.71% in 2022 and later crashed 36.33% in 2025.
  • Year by year, Research & Development stood at $54.0 million in 2021, then skyrocketed by 39.71% to $75.4 million in 2022, then dropped by 27.52% to $54.7 million in 2023, then decreased by 17.73% to $45.0 million in 2024, then plummeted by 36.33% to $28.6 million in 2025.
  • Business Quant data shows Research & Development for ALLO at $28.6 million in Q4 2025, $31.2 million in Q3 2025, and $40.2 million in Q2 2025.